<DOC>
	<DOCNO>NCT02395016</DOCNO>
	<brief_summary>Nimotuzumab humanize monoclonal antibody epidermal growth factor receptor ( EGFR ) . Clinical trial ongoing globally evaluate Nimotuzumab different indication . Nimotuzumab approve treat squamous cell carcinoma head neck ( SCCHN ) , glioma nasopharyngeal carcinoma different countries.The clinical phase Ⅲ trial design assess overall survival（OS）of combination Nimotuzumab administer concurrently Gemcitabine patient RAS wild type locally advance metastatic pancreatic cancer</brief_summary>
	<brief_title>A Study Nimotuzumab Combinated With Gemcitabine K-RAS Wild-type Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>Nimotuzumab humanize monoclonal antibody epidermal growth factor receptor ( EGFR ) . Clinical trial ongoing globally evaluate Nimotuzumab different indication . Nimotuzumab approve treat squamous cell carcinoma head neck ( SCCHN ) , glioma nasopharyngeal carcinoma different countries.The clinical phase Ⅲ trial design assess overall survival（OS）of combination Nimotuzumab administer concurrently Gemcitabine patient RAS wild type locally advance metastatic pancreatic cancer.Secondary objective include time progression（TTP） , progression-free survival（PFS） , Objective Response Rate（ORR） , Disease Control Rate（DCR） , Clinical Benefit Response（CBR）and safety .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Age:1875 year old KPS≥60 Histological cytological diagnosis unsuitable radical radiotherapy surgical treatment locally advance metastatic pancreatic adenocarcinoma ( ≥6 month last adjuvant chemotherapy ) Has least one objective measurable lesion evaluate accord Response Evaluation Criteria Solid Tumors1.1 ( Helical CT examination long diameter target lesions≥10mm , lymph node metastasis need short path ≥15mm ) Life expectancy ≥12 week KRAS tumor tissue detect wildtype Aspartate transaminase（AST）/aminotransferase（ALT）≤2.5×ULN，AST /ALT≤5×ULN（if liver metastases）；Total bilirubin≤2×ULN，Total bilirubin≤3×ULN（if liver metastases）；Absolute neutrophil count≥1.5×109/L；Blood platelet≥100×109/L；Hemoglobin≥90 g/L；Creatinine clearance≥60ml/min Volunteered participate study , write informed consent good compliance Patients childbearing age spouses willing take contraceptive measure Before study receive follow treatments：As mean antitumor palliative chemotherapy molecular target therapy.Target lesion receive radiotherapy without progression.within 4 week participate clinical trial therapeutic/ interventionist clinical trial . Undergone major surgery within 4 week . The brain metastasis leptomeningeal metastasis . Has history malignancy pancreatic cancer ( except cure cervix situ basal cell carcinoma , fiveyear cure cancer ) . The merger symptom ascites require clinical treatment . Accompanied serious disease , include limited : Congestive heart failure difficult control ( NYHA III IV ) , Unstable angina , Poorly control arrhythmia , Uncontrolled moderate severe hypertension ( systolic blood pressure（SBP） &gt; 160 mm Hg diastolic blood pressure（DBP） &gt; 100 mm Hg ) .Active infection.Diabetes difficult control.Has mental illness impact inform consent / compliance program.HIV infection.There serious illness researcher consider unsuitable participate study . Known allergy antiEGFR antibody formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>